Literature DB >> 22064268

Antibody response to the influenza vaccine in healthcare workers.

Ema Sacadura-Leite1, Antonio Sousa-Uva, Helena Rebelo-de-Andrade.   

Abstract

People vaccinated against influenza develop hemagglutination inhibition (HAI) antibodies (Ab) that bind to the virus and neutralize it. Ab titer levels are variable depending on factors insufficiently studied, and tend to decrease over time. In the present study, we analyzed antibodies responses before and after influenza vaccination in nurses working in a hospital, with the aim of: - identifying seroconversion rates to trivalent influenza vaccine one month after immunization; - evaluating if, six months after vaccination, influenza HAI Ab titer fall comparing to one-month post vaccination HAI Ab titer; - studying the association between the lack of HAI Ab response (seroconversion) assessed one month after immunization and: ◦ past influenza vaccinations, ◦ baseline (before vaccination) HAI Ab titer, ◦ baseline (before vaccination) HAI Ab titer ≥ 40 (considered as a protection titer). Hemagglutination inhibition reaction was used to assess specific HAI Ab titers against influenza A(H(1)N(1)), A(H(3)N(2)) and B virus strains included in the influenza vaccine and we used progressive dilutions of two times, starting on 1:10 until 1:20.480. Seroconversion rates, one month after vaccination, were 66.7% for A(H(1)N(1)) strain, 63.2% for A(H(3)N(2)) strain and 56.3% for B strain. The most immunogenic strain used in 2007/08 influenza vaccine was A(H(1)N(1)). Seroconversion rates after one month were negatively associated with past influenza vaccinations, baseline HAI Ab titers ≥ 40 and baseline HAI Ab titers. Six months after vaccination, 50% of participants showed a drop in HAI Ab titers to an half, for each of the considered strains, but they remain high enough to protect against the disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22064268     DOI: 10.1016/j.vaccine.2011.10.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Individual and Population Trajectories of Influenza Antibody Titers Over Multiple Seasons in a Tropical Country.

Authors:  Xiahong Zhao; Yilin Ning; Mark I-Cheng Chen; Alex R Cook
Journal:  Am J Epidemiol       Date:  2018-01-01       Impact factor: 4.897

2.  Analysis of Viral and Host Factors on Immunogenicity of 2018, 2019, and 2020 Southern Hemisphere Seasonal Trivalent Inactivated Influenza Vaccine in Adults in Brazil.

Authors:  Artur Capão; Maria L Aguiar-Oliveira; Braulia C Caetano; Thayssa K Neves; Paola C Resende; Walquiria A F Almeida; Milene D Miranda; Olindo A Ssis Martins-Filho; David Brown; Marilda M Siqueira; Cristiana C Garcia
Journal:  Viruses       Date:  2022-07-30       Impact factor: 5.818

3.  Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.

Authors:  Lilin Lai; Nadine Rouphael; Yongxian Xu; Amy C Sherman; Srilatha Edupuganti; Evan J Anderson; Pamela Lankford-Turner; Dongli Wang; Wendy Keitel; Monica M McNeal; Kaitlyn Cross; Heather Hill; Abbie R Bellamy; Mark J Mulligan
Journal:  Vaccines (Basel)       Date:  2020-03-13

4.  Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study.

Authors:  Olga Pleguezuelos; Emma James; Ana Fernandez; Victor Lopes; Luz Angela Rosas; Adriana Cervantes-Medina; Jason Cleath; Kristina Edwards; Dana Neitzey; Wenjuan Gu; Sally Hunsberger; Jeffery K Taubenberger; Gregory Stoloff; Matthew J Memoli
Journal:  NPJ Vaccines       Date:  2020-03-13       Impact factor: 7.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.